Breaking News: BIIB – Market Insights, Analysis & Latest Updates

S&P 500 ends down as hot US inflation data hints at fewer rate cuts

S&P 500 fell due to inflation concerns impacting Fed rate policies, while CVS and Gilead reported strong earnings. Market activity was mixed with low trading volume.

investing.com • 12/02/2025 - 10:28 AM

Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return

The biopharmaceutical industry seeks to rebound in 2025, navigating uncertainty from regulatory changes and potential impacts from President Trump's administration on drug pricing and vaccine policies.

investing.com • 14/01/2025 - 19:50 PM

BIIB
MRK

BMO cuts rating on Merck and Biogen, on lack of near term catalyst

BMO Capital Markets downgraded Merck and Biogen due to revenue concerns and lack of growth catalysts, lowering stock targets and indicating limited near-term opportunities for recovery.

investing.com • 20/12/2024 - 14:34 PM

BIIB
LLY

Eli Lilly's Alzheimer's treatment approved in China

Eli Lilly’s Kisunla is approved in China for early Alzheimer's, marking a new treatment option alongside Leqembi, with specific dosing and safety profiles.

investing.com • 18/12/2024 - 01:50 AM

Eli Lilly Alzheimer’s drug donanemab approved in China

Eli Lilly's Kisunla treatment for Alzheimer's has been approved in China, following its approval in the U.S., Japan, and the UK, marking an important milestone in Alzheimer’s therapies.

investing.com • 18/12/2024 - 01:15 AM

BIIB

Stifel downgrades Biogen on slow Alzheimer’s drug launch, uncertainty ahead

Stifel downgraded Biogen's stock to hold due to slow Alzheimer's drug rollout and regulatory delays, predicting shares remain stagnant until 2025 without major changes.

investing.com • 16/12/2024 - 18:06 PM

BIIB

Private Medicare plans must cover Biogen's ALS drug, US agency says

CMS directs Medicare Advantage insurers to cover Biogen's ALS drug Qalsody, reversing previous denials labeled as 'experimental'. The ALS Association aids in addressing unjust coverage refusals.

investing.com • 12/12/2024 - 18:02 PM

BofA reinstates pharma coverage

Bank of America reviews 11 U.S. pharma stocks, highlighting growth potential and challenges amid patent cliffs and pricing pressures while recommending buy, neutral, and underperform ratings.

investing.com • 10/12/2024 - 14:30 PM

BIIB

Biogen cut at Jefferies as '2025 has a tough setup'

Jefferies downgraded Biogen to Hold, cutting its price target due to sales growth concerns and reliance on diminishing royalties, raising doubts about future pipeline development.

investing.com • 09/12/2024 - 17:17 PM

BIIB

Needham downgrades Biogen on slow growth of Alzheimer's drug

Needham downgraded Biogen due to slow growth of Leqembi and reduced revenue estimates, with potential catalysts from business deals and positive Phase 3 data for Litifilimab.

investing.com • 18/11/2024 - 16:20 PM

Currency